Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.

A Multi-centre, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.

This is a multi-centre, multi-country retrospective cohort study. At least 450COVID-19 cases from up to 20 participating study sites who meet all eligibility criteria will be included in the analysis. Deidentified data will be extracted from electronic medical record (EMR) databases, clinical registries, case series or additional sources from participating sites and countries, and then entered into a structured e-CRF system. addition, each site/country will be surveyed to determine the local standard of care therapy for COVID-19 infection and to determine if standard protocols were/are in place for the use of Remdesivir and if/how the protocols changed over time.

Inclusion Criteria:

All Adult participants with COVID-19 confirmed by PCR who meet the following criteria:

• Hospitalised after August 31st,2020
• Receivedat least one dose of Remdesivir(RDV)at anytime during hospitalisation

Exclusion Criteria:

• Received Remdesivir as part of a clinical trial, compassionate use or expanded access program
• Received Remdesivir prior to this admission at any other health facility than the research sites and whose health records are available.